1
|
Rougier G, Rochand A, Bourdais R, Meillan N, Tankere F, Herman P, Riet F, Mazeron JJ, Burnichon N, Lussey C, Jacob J, Simon JM, Maingon P, Feuvret L. Long-Term Outcomes in Head and Neck Paragangliomas Managed with Intensity-Modulated Radiotherapy. Laryngoscope 2023; 133:607-614. [PMID: 35638238 DOI: 10.1002/lary.30226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 05/11/2022] [Accepted: 05/11/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVES Head & Neck Paragangliomas have been historically relying on surgery mostly, with worsened quality of life and major sequelae. Conventional external radiation therapy seems to offer an equivalent control rate with a low toxicity profile. The aim of this study was to assess the safety and efficiency of intensity-modulated radiation therapy in Head & Neck paragangliomas. METHODS This is a retrospective monocentric study conducted in a referral center, including all patients treated with IMRT, whether as an exclusive or post-operative treatment for a tympanic and jugular, carotid, or vagal paraganglioma. Data collection was performed through the manuscript and computerized medical files, including consultation, operative, imaging, pathological analyses, delineation, and treatment planning reports. Success was defined as the complete or partial regression or stabilization without progression, or relapse in accordance with the RECIST criteria. Acute toxicities and long-term sequelae were assessed. RESULTS Our cohort included 39 patients included between 2011 and 2021: 18 patients treated for a TJ PG (45.9%), 11 patients for a carotid PG (28.4%), and 9 for a vagal PG (23.1%). Twenty-nine patients had IMRT as an exclusive treatment (74.4%), whereas 10 patients had a post-operative complementary treatment (25.6%). Median follow-up in our cohort was 2318 days (average = 2200 days, 237-5690, sd = 1281.9). Among 39 patients, 37 were successfully controlled with IMRT (94.8%), and the toxicity profile was low without any major toxicity. CONCLUSION IMRT seems an ideal treatment, whether exclusive or post-operative for Head & Neck paragangliomas. LEVEL OF EVIDENCE 3 Laryngoscope, 133:607-614, 2023.
Collapse
Affiliation(s)
- Guillaume Rougier
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France.,Institut Curie, Department of ENT, Head & Neck Surgery, Paris, France
| | - Adrien Rochand
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Rémi Bourdais
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Nicolas Meillan
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Frédéric Tankere
- Sorbonne Universités, Department of ENT, Head and Neck Surgery, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Philippe Herman
- Department of ENT, Head and Neck Surgery, Hôpital Lariboisière, APHP, Paris, France.,Université de Paris, Paris, France
| | - François Riet
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Jean-Jacques Mazeron
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Nelly Burnichon
- Université de Paris, Paris, France.,Genetics Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France.,PARCC, INSERM UMR970, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France
| | - Charlotte Lussey
- Genetics Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France.,PARCC, INSERM UMR970, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France.,Sorbonne Universités, Department of Nuclear Medicine, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Julian Jacob
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Jean-Marc Simon
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Philippe Maingon
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| | - Loïc Feuvret
- Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France
| |
Collapse
|
2
|
Deflorenne E, Peuchmaur M, Vezzosi D, Ajzenberg C, Brunaud L, Chevalier N, Christin-Maitre S, Decoudier B, Driessens N, Drui DD, Gilly O, Goudet P, Illouz F, Jublanc C, Lefebvre H, Lopez AG, Lussey C, Morini A, Raffin-Sanson ML, Raingeard I, Renoult-Pierre P, Storey C, Tabarin A, Vantyghem MC, Vidal-Petiot E, Baudin E, Bertherat J, Amar L. Adrenal ganglioneuromas: a retrospective multicentric study of 104 cases from the COMETE network. Eur J Endocrinol 2021; 185:463-474. [PMID: 34291731 DOI: 10.1530/eje-20-1049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 07/06/2021] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Adrenal ganglioneuromas are rare, differentiated, neuroblastic tumors that originate from the peripheral sympathetic nervous system. Because of their rarity, information is limited, derived from small cases series. Our objective was to characterize this tumor and provide help for its management. METHODS A retrospective multicenter analysis of adrenal ganglioneuromas from 20 French centers belonging to the COMETE network and one Belgian center. RESULTS Among the 104 cases identified, 59.6% were women (n = 62/104), median age at diagnosis was 29 years, with 24 pediatric cases. 60.6% (n = 63/104) were incidentalomas. Ganglioneuromas were non-secreting tumors in 90.8% of cases (n = 89/98), whereas the preoperative hormonal evaluation was indeterminate for 9.2% of patients (n = 9/98). CT imaging, performed on 96 patients, revealed large tumors (median diameter of 50 mm) with a non-contrast density > 10 Hounsfield units in 98.1% (n = 52/53) and calcifications in 64.6% of cases (n = 31/48). Increased uptake on 123I-MIBG scintigraphy and 18F-FDG-PET/CT was observed in 26.7% (n = 8/30) and 42.2% (n = 19/45) of the tumors, respectively. All 104 patients underwent surgery. No recurrence was observed among the 42 patients who had an imaging follow-up (mean 29.6 months, median 18 months (4-156)). CONCLUSION Adrenal ganglioneuromas are large tumors, mostly nonfunctioning, without benign imaging features. Although the duration of follow-up was limited in our series, no recurrence was identified. A review of the literature confirms the absence of postoperative recurrence. Based on all available data, in the absence of special circumstances (genetic form, uncertain histological diagnosis), long-term follow-up is not necessary after complete surgery for patients with an adrenal ganglioneuroma.
Collapse
Affiliation(s)
- Elisa Deflorenne
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre de Référence des Maladies Rares de la Surrénale, Unité Fonctionnelle d 'Hypertension Artérielle, Université de Paris, Paris, France
- Sorbonne Université, Médecine Paris, France, undefined
- UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France
| | - Michel Peuchmaur
- Service de Pathologie, HU Robert Debré, APHP, Paris, France
- Université de Paris, Paris, France
| | | | - Christiane Ajzenberg
- Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Service de Médecine Interne et Endocrinologie, Créteil, France
| | - Laurent Brunaud
- Département de Chirurgie Viscérale, Métabolique et Cancérologique Unité Médico-chirurgicale de chirurgie Métabolique, Endocrinienne et Thyroïdienne (UMET), Université de Lorraine, CHU de Nancy, Hôpital Brabois Adultes, Nancy, France
| | - Nicolas Chevalier
- Université Côte d'Azur, Service d'Endocrinologie, Diabétologie et Reproduction, CHU de Nice, Hôpital de l'Archet 2, Nice, France
| | - Sophie Christin-Maitre
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Service d'Endocrinologie et Maladies de la Reproduction, Paris, France
| | - Bénédicte Decoudier
- Centre Hospitalier Universitaire de Reims, Service d'Endocrinologie-Diabète-Nutrition, Reims, France
| | - Natacha Driessens
- Département d'Endocrinologie, CUB-Hôpital Erasme, Bruxelles, Belgique
| | - Delphine D Drui
- Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec, Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, L'institut du Thorax, Nantes, France
| | - Olivier Gilly
- CHU de Nîmes, Service des Maladies Métaboliques et Endocriniennes, Nîmes, France
| | - Pierre Goudet
- CHU de Dijon, Chirurgie Endocrinienne et Métabolique, Dijon, France
| | - Frédéric Illouz
- Centre de Référence des Maladies Rares de la Thyroïde et des Récepteurs Hormonaux, Département d'Endocrinologie Diabétologie Nutrition, Angers, France
| | - Christel Jublanc
- Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service d'Endocrinologie-Métabolisme, Institut E3M, Paris, France
| | - Hervé Lefebvre
- Université de Rouen Normandie, UNIROUEN, INSERM U1239, CHU de Rouen, Service d'Endocrinologie, Diabète et Maladies Métaboliques et CIC-CRB 1404, Rouen, France
| | - Antoine-Guy Lopez
- Université de Rouen Normandie, UNIROUEN, INSERM U1239, CHU de Rouen, Service d'Endocrinologie, Diabète et Maladies Métaboliques et CIC-CRB 1404, Rouen, France
| | - Charlotte Lussey
- Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Médecine Nucléaire, Paris, France
| | - Aurelien Morini
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Laboratoire d'Anatomo-Pathologie, Paris, France
| | - Marie-Laure Raffin-Sanson
- Assistance Publique-Hôpitaux de Paris, CHU Ambroise-Paré, Service d'Endocrinologie et Nutrition, Boulogne-Billancourt, France
| | - Isabelle Raingeard
- CHRU de Montpellier, Service d'Endocrinologie, Diabète, Maladies Métaboliques, Montpellier, France
| | - Peggy Renoult-Pierre
- Centre Hospitalier Universitaire de Tours, Département d'Endocrinologie, Tours, France
| | - Caroline Storey
- Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique, Paris, France
| | - Antoine Tabarin
- CHU de Bordeaux, Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, Bordeaux, France
| | - Marie Christine Vantyghem
- Centre Hospitalier Régional Universitaire de Lille, Service d'Endocrinologie et Maladies Métaboliques, Lille, France
| | - Emmanuelle Vidal-Petiot
- Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Physiologie, Paris, France
| | - Eric Baudin
- Institut Gustave Roussy, Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Villejuif, France
| | - Jerome Bertherat
- Université Paris Descartes, Hôpital Cochin, Centre de Référence des Maladies Rares de la Surrénale, Service d'Endocrinologie, Paris, France
| | - Laurence Amar
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre de Référence des Maladies Rares de la Surrénale, Unité Fonctionnelle d 'Hypertension Artérielle, Université de Paris, Paris, France
- UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France
| |
Collapse
|